Between 1994 and 1996 we detected 28 out of 7054 (0.4%) clinical isolates of Escherichia coli with abnormal or reduced inhibition diameters to co-amoxiclav and ceftazidime in a disc diffusion test. The increased MIC of ceftazidime (1-32 mg/L) and the effect of synergy between this antibiotic and co-amoxiclav according to the disc diffusion test suggest the presence of an extended-spectrum -lactamase. However, enzymatic characterization and the nucleotide sequence confirm the hyperproduction of the SHV-1 enzyme.
Introduction
SHV-1, a plasmid mediated -lactamase, is a widespread enzyme that hydrolyses penicillins, except temocillin, firstgeneration cephalosporins, cefamandole, and cefoperazone. Cephamycins, monobactams and carbapenems are considerably more stable to hydrolysis.
1 SHV-1 also shows slight activity against aminothiazolil-cephalosporins. 2 S H V -1 accounts for little more than 5% of all plasmidencoded -lactamases in clinical isolates of Enterobacteriaceae and less than 8% in Escherichia coli. 1, 3 Recent reports indicate that hyperproduction of TEM-1 or SHV-1 plasmid-encoded -lactamases in E. coli and Klebsiella spp. are responsible for resistance to combinations containing inhibitor and enzyme-labile drugs. The hyperproduction of SHV-1 detected in one E. coli and in some Klebsiella pneumoniae clinical strains has been assumed to be responsible also for decreased susceptibility to aminothiazolil-cephalosporins. 2, 4, 5 This report describes the characterization of 28 (0.4%) of 7054 strains of E. coli with reduced susceptibility to co-amoxiclav and ceftazidime due to the hyperproduction of SHV-1. These strains were isolated from different clinical sources at the Sant Pau Hospital (Barcelona, Spain) between 1994 and 1996.
Materials and methods

Bacterial strains
Twenty-eight clinically relevant E. coli strains with reduced susceptibility to co-amoxiclav and ceftazidime were evaluated. Twenty-two were isolated from urine, three from blood and three from wounds. Ten were from patients with nosocomial infections and 18 were from patients with community-acquired infection. There was no known epidemiological relationship between any of these patients.
E. coli K-12 C600 Nal R strain was used in transfer experiments. For analytical isoelectric focusing and PCR, strains producing SHV-1, SHV-2, SHV-4 and SHV-5 -lactamases were used as known standards.
ceftazidime and aztreonam were determined by an agar dilution procedure following NCCLS recommendations.
6
Analytical isoelectric focusing
The -lactamase extractions and isoelectric focusing were carried out as described by Barthélemy et al., 7 with a pH gradient from 4 to 11 (SERVALYT 4-9 T, 9-11 T; Serva, Heidelberg, NY, USA). Enzyme activities were determined by the iodometric method. 7 
-Lactamase assays
Hydrolysis of -lactam antibiotics was monitored spectrophotometrically using a Biochrom 4060 spectrophotometer (Pharmacia, Uppsala, Sweden). One unit of enzymatic activity was defined as the amount of enzyme that hydrolyses 1 µmol of substrate in 1 min at 25°C in 0.1 M phosphate buffer of pH 7.0. The molar extinction coefficients used were as follows: for penicillin (233 nm 
Polymerase chain reaction (PCR)
The bla SHV genes were amplified using the primers described by Nüesch-Inderbinen et al. 8 The 1017 bp fragments were subjected to NheI enzyme restriction.
DNA sequence analysis
The sequence was obtained from PCR products using dye-labelled terminators. 4 Samples were applied to an automated Model 310 Genetic Analyzer (Perkin-Elmer/ Applied Biosystems, Inc., Foster City, NJ, USA).
Biotyping
The biotypes were determined according to the system proposed by Richard, 9 which entails 12 tests divided into four groups of three: fermentation of dulcitol, sucrose and raffinose; production of lysine decarboxylase and ornithine decarboxylase and detection of -glucuronidase; fermentation of rhamnose and sorbitol, and glucose gas production; and fermentation of lactose, adonitol, and sorbose. Points are allocated for each positive test: one point for the first test in each group; two for the second; and four for the third test. Biotypes are expressed in a four-digit code. 
Pulsed-field gel electrophoresis (PFGE)
DNA for PFGE analysis was prepared following the method of Rasheed et al. 4 Digestion was carried out with XbaI (Pharmacia P-L Biochemicals, Uppsala, Sweden). PFGE was performed using the OFAGE system (Gene Navigator, Pharmacia LKB Biotechnology, Sweden), in 1% agarose gels (SeaKem HGT; FMC, Rockland, USA). The running conditions were: 0.5 TBE buffer (0.
Results and discussion
A total of 7054 E. coli strains were isolated from clinical sources in our laboratory between 1994 and 1996. Twentyeight of these strains showed the presence of an irregular crenellated zone, consisting of 'scatter colonies' with small or normal-sized zones of inhibition, when discs containing co-amoxiclav and/or ceftazidime were tested.
The agar dilution method showed that all strains were resistant to penicillins (ampicillin 1024 mg/L, ticarcillin 512 mg/L, and piperacillin 64 to 256 mg/L). Most of them were resistant to first-generation cephalosporins and had reduced susceptibility to co-amoxiclav and ceftazidime (Table I) , but were fully susceptible to cefoxitin and cefuroxime (2-8 mg/L), cefotaxime ( 0.25 mg/L), and aztreonam ( 0.25 mg/L). All strains showed synergy between co-amoxiclav and ceftazidime, but with a small and irregular area of enhancement. These characteristics were compatible with the presence of an extended-spectrum -lactamase.
Transconjugants were obtained from strains 363-D, 424-D, 485-D, 531-D and 591-D. These strains showed the same level of resistance to co-amoxiclav and ceftazidime as the parental strains. Analytical isoelectric focusing revealed that all strains, both parental and transconjugants, had a single band of -lactamase activity at pI 7.6.
As described for K. pneumoniae, the low level of resistance to third-generation cephalosporins, the decreased susceptibility to co-amoxiclav, the isoelectric point 7.6, and the kinetic constants identical to those of SHV-1 suggest the possibility of hyperproduction of SHV-1. (Table II) suggests a similar mechanism to that reported by Petit et al. 2 These authors described a clinical isolate of K. pneumoniae with SHV-1 hyperproduction in clinical E. coli isolates decreased susceptibility to ceftazidime (MIC 8 mg/L), and susceptibility to cefotaxime (0.015 mg/L) and aztreonam (2 mg/L), which hyperproduced an SHV-1 -lactamase. SHV-1 activity against ceftazidime was not detected by hydrolysis but was observed when the inhibition constant (K i ) was determined by competition procedures. 2 In our strains, cefotaxime and ceftazidime hydrolysis was also studied, but no -lactamase activity was detected (data not shown).
Nüesch-Inderbinen et al. 8 described a method to differentiate the SHV-1 enzyme from their extendedspectrum -lactamases, in which the genes coding for the SHV-2 to SHV-5 -lactamases are digested by NheI. By PCR, we obtained an amplicon of 1017 bp in all 28 strains which was not digested by NheI, suggesting that our strains produced an SHV-1 enzyme and not a known extendedspectrum -lactamase.
Recently, Rasheed et al. 4 described the production of large amounts of SHV-1 -lactamase in one E. coli strain due to acquisition of a bla SHV gene, which was followed by a mutation that enhanced the strain's ceftazidime resistance (becoming SHV-8). In order to discard the possibility of a new amino acid mutation that had enhanced the -lactamase activity, the sequences of the PCR products from strains 822-D, 824-D and 824-DH were determined. For all of them the deduced amino acid sequence was identical to that of SHV-1 (data not shown).
Nüesch-Inderbinen et al. 10 developed a system based on site-directed mutagenesis, which enabled SHV enzymes to be compared accurately under isogenic conditions. They concluded that increased resistance due to hyperproduction of -lactamase might be an effect of altered promoter structures. Nevertheless, discrepancies between the catalytic properties of -lactamases and -lactam MIC values may also be related to other parameters, including permeability and relative affinities for penicillin-binding proteins. 1, 2, 4 The mechanism by which the strains hyperproduced SHV-1 -lactamases has not been described.
These 28 strains did not correspond to a unique epidemic strain. Several groups can be established according Table I . Susceptibility patterns, pulsotypes, biotypes, and serogroups of the 28 strains studied to serogroup, biotype and pulsotype. Five of them consist of more than one strain (cluster A1 with five strains; A2, B1 and D with two strains; and C1 with three). Six other strains are closely related to at least one of these clusters (strains 712-D and 464-D to cluster A1; 613-D and 824-D to cluster B1; and 485-D and 531-D to cluster C1). However, seven strains are not related, and the possibility that a plasmid or mobile element coding for an SHV-1 -lactamase that could be hyperproduced is present and spreading within the population requires further study.
The four different O antigens detected, O2, O4, O6 and O18, are frequently found in association with urinary tract infection and sepsis. A clearer correlation between PFGE patterns and serogroups was observed.
We do not know if the hyperproduction of SHV-1 has a similar clinical impact to the extended-spectrum -lactamases. Furthermore, the hyperproduction could probably be selected progressively in vivo since it was easily selected in vitro. 
